Day

October 2, 2018
New method paves the way for mass production of snake antivenom without the many side effects of today’s products. Danish scientists – including a recipient of the Lundbeck Foundation Talent Prize – played an important role in the research and development. Every year, around 100,000 people worldwide die from snakebites, and at least 400,000 of...
Copenhagen, Denmark – September 27th, 2018: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win® technology, announces that the first patient has received the first dose in an international Phase I/II clinical trial studying the investigational candidate IO102 in combination with KEYTRUDA® (pembrolizumab) for patients with non-small...
Pruritus Relief thru Itch-Scratch Modulation (PRISM) Trial to enroll 240 patients and evaluate efficacy of Nalbuphine ER at 14 weeks New Haven, CT, September 27, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine® ER for chronic pruritic and other serious neurological conditions, today announced initiation of a pivotal clinical trial evaluating Nalbuphine ER in patients...

News

Genetic sprint – all the way down through the Americas
9. November 2018
Denmark’s most transparent foundation for the third year running
8. November 2018
The Lundbeck Foundation honours three brilliant, upcoming research talents
24. October 2018

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge